Maximizing Innovation Cash Flow: The 90% Refund Exchange for Connecticut’s Qualified Small Biotechnology Companies

I. Executive Summary: The Strategic Value of Refundable R&D Credits

The Qualified Small Biotechnology Company (Refund Percentage) refers to the enhanced rate at which eligible Connecticut biotech C-corporations with minimal tax liability can exchange their unused R&D tax credits for cash. This refundable mechanism offers a 90% cash back rate on the value of the credit, significantly boosting immediate operating cash flow for critical research.1

1.1. High-Level Overview of the Enhanced Incentive

The State of Connecticut maintains a robust structure of tax incentives designed to promote in-state research and development (R&D) activities, primarily through the incremental Research and Experimental (RC) Credit (CGS § 12-217j) and the non-incremental Research and Development (RDC) Credit (CGS § 12-217n).1 These incentives generally serve as offsets against the Corporation Business Tax liability. However, recognition that early-stage, R&D-intensive companies often operate at a net loss for extended periods—thereby generating significant tax credits they cannot immediately use—led the state to adopt a mechanism allowing for the exchange of these unused credits for a cash refund.3

For a substantial period, the standard exchange rate for a Qualified Small Business (QSB) was 65% of the credit’s value. The legislative framework underpinning this liquidity provision is codified in CGS § 12-217ee. This provision is designed to provide immediate, non-dilutive capital, thereby accelerating the economic impact of the tax incentive within Connecticut.2

1.2. The Significance of the 2025 Enhancement

A pivotal legislative change, effective for income years commencing on or after January 1, 2025, dramatically enhanced this incentive for a select group of taxpayers. Public Act 25-168 (H.B. 7287), signed into law on June 30, 2025, specifically increased the refund exchange percentage for Qualifying Biotechnology Companies from the baseline 65% rate to an exceptional 90%.1

This policy adjustment represents a highly targeted economic development tool. By offering a 90% return—which translates to only a 10% discount on the face value of the credit—the state provides a significant injection of immediate liquidity into the high-growth, cash-intensive life science sector.2 This action is interpreted as a direct effort by the state government to accelerate the research, development, and commercialization timelines for Connecticut-based biological research firms, addressing the chronic challenge of capital scarcity often faced by pre-revenue biotech startups. The enhanced exchange rate directly supports the operational expenses of companies focused on high-risk, high-reward research, solidifying Connecticut’s competitive position against other major national biotech hubs.

II. Statutory and Regulatory Framework of the Connecticut R&D Credit

Understanding the 90% refund percentage requires a detailed comprehension of the underlying statutes that govern how the R&D credits are generated and what constitutes a “biotechnology company.”

2.1. The Dual R&D Credit Structure (CGS §§ 12-217j and 12-217n)

Connecticut provides two primary methods for calculating the R&D credit, both of which may be exchanged for a refund if eligibility criteria are met.

2.1.1. Incremental (RC) Credit

The Incremental Research and Experimental (RC) Credit is calculated under CGS § 12-217j. It is equal to 20% of the research and experimental expenditures (Qualified Research Expenses or QREs) conducted within Connecticut that exceed the amount spent on such expenditures during the preceding income year.4 QREs are defined by reference to Section 174 of the Internal Revenue Code (IRC), encompassing wages for qualified services, supply costs, and certain contract research costs. This method rewards companies demonstrating consistent year-over-year growth in their R&D investment within the state.1

2.1.2. Non-Incremental (RDC) Credit

The Research and Development (RDC) Credit, authorized under CGS § 12-217n, offers an alternative, non-incremental calculation. This option is particularly beneficial for companies whose R&D spending is stable, cyclical, or where the current year’s spending does not exceed the prior year’s base amount significantly. For taxpayers defined as a Qualified Small Business (QSB)—a designation that applies to C-corporations with gross income up to $100 million in the prior year—the RDC provides a credit equal to a flat 6% of the total current year’s R&D expenses.1

For larger entities, or those exceeding the $\$100$ million gross income threshold, the RDC calculation reverts to a tiered structure based on total R&D expenses, with rates ranging from 1% up to a maximum effective rate of 6% for expenses exceeding $200 million.8

2.1.3. Credit Utilization Limits

Both the RC and RDC credits are primarily non-refundable and, when applied against tax liability, are capped at offsetting up to 70% of the corporate business tax due.4 Unused credits that are not exchanged for a refund may be carried forward for up to 15 successive income years.4

2.2. Defining the “Biotechnology Company” (CGS § 12-217j(a)(B))

The premium 90% refund rate is not available to all small businesses, nor even to all QSBs engaged in R&D. It is conditional upon the taxpayer meeting the highly rigorous and technical statutory definition of a “biotechnology company” as set forth in CGS § 12-217j(a)(B).6

The legislative intent behind this highly technical definition is to establish a specific firewall, ensuring that the most generous incentive targets core life sciences rather than tangential industries such as general software development or advanced manufacturing that lacks a biological component.

2.2.1. Definition Components: Techniques and Processes

A company must be demonstrably engaged in the business of applying technologies that are explicitly listed in the statute. These specified scientific techniques include: recombinant DNA techniques, biochemistry, molecular and cellular biology, genetics and genetic engineering, biological cell fusion techniques, and new bioprocesses.6 The use of these specific, high-tech biological processes limits eligibility to companies performing foundational research related to genetic manipulation, cell culture, and biological systems.

2.2.2. Definition Components: Output Requirements

Furthermore, the application of these techniques must serve the purpose of using living organisms, or parts of organisms, to achieve specific outcomes. These required outcomes include: producing or modifying products, improving plants or animals, developing microorganisms for specific uses, identifying targets for small molecule pharmaceutical development, or transforming biological systems into useful processes and products.6

The focus on process and biological transformation ensures that the enhanced state funds benefit the highly capitalized, high-risk biological research sector, aligning directly with the state’s broader economic development initiatives aimed at fostering a robust bioscience cluster, such as the Bioscience Enterprise Corridor Zone incentives.12

III. Qualification for “Small Business” Status and Credit Exchange

To transition from generating an R&D credit to exchanging that credit for a cash refund, the biotechnology company must satisfy a two-part eligibility test defined under CGS § 12-217ee relating to its size and its current tax liability.

3.1. The Financial Threshold: Qualified Small Business (QSBC) Status

The critical financial test for refund eligibility centers on the taxpayer’s gross income in the preceding income year. To qualify for any cash refund—be it the standard 65% or the enhanced 90%—the taxpayer’s gross income for the previous income year must not exceed $70 million.1

This threshold is strictly applied and includes income derived from transactions with related entities. This inclusion prevents larger corporate groups from structuring their operations to segment a profitable entity away from its R&D activities solely to qualify for the small business refund.4 This constraint ensures that the cash liquidity benefit is directed towards truly independent, growing businesses.

3.1.1. Analyzing the Dual Gross Income Thresholds

It is paramount for tax planning to differentiate the $\$70$ million exchange threshold from the $\$100$ million threshold often cited in connection with the RDC calculation.1 A company with prior-year gross income between $\$70$ million and $\$100$ million may still calculate their R&D credit at the maximum 6% RDC rate but would be ineligible to exchange that credit for cash because they exceed the stringent $\$70$ million threshold required under CGS § 12-217ee.4

This distinction reflects a legislative intent to segment cash flow relief: companies between $\$70$ million and $\$100$ million in gross income are considered large enough to rely on the R&D credit carryforward to offset future tax liabilities, while only the smallest entities ($\le \$70$ million) receive the state’s most valuable tool—immediate cash liquidity.

3.2. The Zero-Liability Requirement (Unused Credit Test)

The second necessary qualification for credit exchange is the inability to utilize the credit against the current year’s tax liability.10 This requirement is crucial because the exchange program is intended to assist companies that are pre-profit and therefore cannot benefit from a non-refundable credit.

DRS guidance confirms that a corporation filing the Corporation Business Tax Return (Form CT-1120) may exchange the credit if either of the following conditions is met:

1. The company’s apportioned amount of net income is zero or negative (indicating a net loss or break-even status).4 This is the most typical scenario for early-stage biotechnology firms.
2. The company’s capital base tax (the minimum tax component of the corporation business tax) is equal to the minimum statutory amount, currently $250.4

The credit exchange mechanism is currently available only to corporate structures (C-corporations filing Form CT-1120 or CT-1120CU).2 Although House Bill 7008 proposed extending R&D credits to pass-through entities (PTEs) and sole proprietors, that legislation was not enacted as of late 2025, confirming that the enhanced 90% benefit is strictly limited to corporate taxpayers.1

IV. The Specialized 90% Refund Percentage for Biotechnology

The 90% refund rate is the centerpiece of the incentive, providing an unparalleled level of state support for early-stage biotech research.

4.1. Legislative Mandate and Effective Date

The dramatic increase in the refund rate for qualifying biotechnology companies was secured through the passage of Public Act 25-168 (H.B. 7287).1 This legislation modified the existing provisions of CGS § 12-217ee, allowing the exchange of R&D tax credits for ninety per cent (90%) of their value.5 The legislation became effective on July 1, 2025, and, significantly, applies to income years commencing on or after January 1, 2025.1

4.2. Comparative Financial Advantage of the 90% Rate

The 90% rate represents a significant comparative advantage over the standard 65% QSBC rate, resulting in an additional 25 cents of immediate cash flow for every dollar of tax credit generated.1 The policy rationale is clear: by minimizing the discount rate applied to the R&D asset, the state maximizes the working capital injection into the companies that need it most. This provides a substantial advantage in attracting and retaining high-value biological research activities compared to states offering only future carryforward benefits or lower cash exchange rates.

4.3. Statutory Limitations on Refundability: The $1.5 Million Cap

While the 90% rate is highly beneficial, the state imposes a critical annual limit on the total cash payout. Regardless of the taxpayer’s status (biotech or non-biotech QSBC) or the refund rate (65% or 90%), the amount a qualified small business may receive is capped at $1,500,000 for any one income year.1 This cap restricts the state’s budget exposure while still providing substantial initial funding.

4.4. Calculation of Credit Needed to Maximize Refund

The $\$1.5$ million cap dictates the optimal R&D credit generation target for taxpayers prioritizing immediate cash flow.

To achieve the maximum cash refund of $\$1,500,000$ under the enhanced 90% exchange rate, a biotechnology company must generate an R&D credit (RC or RDC) value of exactly $1,666,667. This is calculated by dividing the cap by the exchange rate ($\$1,500,000 / 0.90 \approx \$1,666,667$).

Any R&D credit generated above this $\$1,666,667$ threshold will still only yield the maximum $\$1.5$ million cash refund, with the remainder of the credit being automatically carried forward for up to 15 years to offset future tax liabilities.4 Financial planning must therefore integrate the $\$1.5$ million cap into QRE budgeting, focusing on generating sufficient QREs (approximately $27.78 million if using the 6% RDC rate) to meet this cash threshold most efficiently.

Table 5, provided below, summarizes the refund eligibility structure for quick reference.

Table 5. Comparative R&D Credit Refund Exchange Rates

V. Connecticut Department of Revenue Services (DRS) Compliance and Procedure

Successful navigation of the Connecticut R&D refund exchange is highly dependent on strict adherence to the administrative procedures established by the Department of Revenue Services (DRS). The process requires a unique hybrid filing strategy.

5.1. Required Application Forms

The request for the R&D credit exchange must be submitted via Form CT-1120 XCH, titled Application for Exchange of Research and Development or Research and Experimental Expenditures Tax Credits by a Qualified Small Business.14 This form serves as the primary mechanism for certifying that the company meets the stringent gross income, unused credit, and (for the 90% rate) biotechnology status requirements under CGS § 12-217ee.

Taxpayers must also indicate the election to exchange the credits and enter the requested refund amount on Page 1 of the primary Corporation Business Tax Return, Form CT-1120.15

5.2. Necessary Supporting Documentation

The CT-1120 XCH application is incomplete without the required schedules detailing the credit calculation. The taxpayer must attach the form used to calculate the specific credit being exchanged.14 This includes either:

• Form CT-1120RC: Used for the 20% Incremental R&E Credit calculation.
• Form CT-1120 RDC: Used for the Non-Incremental R&D Credit (including the 6% QSB calculation).15

Furthermore, all required supporting schedules and comprehensive documentation, which substantiates the eligibility of the Qualified Research Expenses, must be included with the CT-1120 XCH submission package.15

5.3. Critical Separate Filing Requirement

A major administrative compliance checkpoint that frequently poses a procedural hurdle is the strict requirement to file the refund application separately from the corporate tax return. DRS guidance mandates that Form CT-1120 XCH must be filed separately from the primary Form CT-1120 or the combined return Form CT-1120CU.15

While modern corporate tax returns are typically filed electronically through systems like myconneCT or the Modernized e-File Program (MeF) 18, the completed application (Form CT-1120 XCH) and all supporting documentation must be simultaneously mailed to the Department of Revenue Services P.O. Box address.16

Failure to adhere to this precise, hybrid filing process—where the CT-1120 is filed electronically and the CT-1120 XCH package is physically mailed—can result in processing delays or, in extreme cases, the denial of the refund request, thereby defeating the incentive’s goal of providing rapid cash liquidity. Tax departments must implement robust internal controls to ensure the physical mailing requirement for the XCH form is met at the same time as the electronic submission of the main return.

5.4. Confirmation of Biotechnology Status

Although the legislation providing the 90% rate is effective for 2025 income years, formal DRS public policy statements or updated form instructions (specifically referencing the 90% rate on the CT-1120 XCH) may evolve following the July 1, 2025, effective date.5 Taxpayers must be prepared to rigorously substantiate their claim to the premium 90% rate by providing documentation confirming their adherence to the specific scientific processes and output requirements defined in CGS § 12-217j(a)(B).11 The technical nature of the statutory definition requires that the R&D documentation explicitly link the company’s activities to recombinant DNA techniques, genetic engineering, or similar biological processes to withstand audit scrutiny.

VI. Case Study: Quantitative Impact of the 90% Refund

This scenario illustrates the substantial cash flow benefits of the 90% refund rate for a high-spending Qualified Small Biotechnology Company (QSBC), demonstrating how the rate interacts with the statutory annual cap.

6.1. Scenario Setup (Company PharmaGenesis)

• Status: A C-Corporation engaged in applying molecular and cellular biology to develop novel small molecule pharmaceutical targets, meeting the stringent “biotechnology company” definition.6
• Financials (Previous Year): Gross Income = $60,000,000. This meets the criteria for a Qualified Small Business for exchange purposes ($\le \$70$ million).1
• Tax Position (Current Year): The company has substantial R&D expenses resulting in negative apportioned net income for the current year. This satisfies the unused credit requirement for the exchange.4
• R&D Spend (QREs): Current Year QREs = $35,000,000.
• Calculation Method: Given the large, stable QRE base, PharmaGenesis strategically selects the Non-Incremental RDC Credit, which allows for a 6% rate applied to total QREs.1

6.2. Step-by-Step R&D Credit Generation

The total R&D credit generated by PharmaGenesis is calculated as follows:

$$\text{RDC Credit Generated} = \$35,000,000 \times 6\% = \$2,100,000$$

PharmaGenesis has a total unused R&D credit of $2,100,000 available for exchange.

6.3. Application of the Refund Percentage and Cap

The calculated credit is applied against the enhanced 90% refund rate.

1. Theoretical 90% Refund Calculation:
   
   $$\text{Theoretical Refund} = \$2,100,000 \times 90\% = \$1,890,000$$
2. Application of the Statutory Cap:
   The calculated theoretical refund of $\$1,890,000$ must be compared against the maximum annual cash refund limit of $1,500,000.1 Since the theoretical amount exceeds the cap, the actual cash refund is restricted to the maximum statutory limit.
   Actual Cash Refund Received: $1,500,000.

6.4. Handling Unutilized Credit

Since the company received a cash refund of $\$1.5$ million, it needs to determine how much of its original $\$2.1$ million credit was utilized to generate that cash payment.

The credit amount utilized is calculated by dividing the cash refund received by the 90% rate:

$$\text{Credit Utilized} = \frac{\$1,500,000}{0.90} \approx \$1,666,667$$

The remaining balance of the generated credit is then carried forward:

$$\text{Unused Credit Carried Forward} = \text{Total Credit} – \text{Credit Utilized}$$

$$\text{Unused Credit Carried Forward} = \$2,100,000 – \$1,666,667 = \$433,333$$

PharmaGenesis immediately receives $1.5 million in non-dilutive working capital and retains a valuable $433,333 tax asset, which can be carried forward for up to 15 years to offset future Corporation Business Tax liabilities.4

This scenario underscores a crucial planning point: R&D expenditures generating credit beyond the $\$1,666,667$ threshold primarily contribute to the carryforward balance, not immediate cash flow. Tax modeling should strategically target QREs that maximize the $90\%$ return up to the $\$1.5$ million cap, rather than simply maximizing total QREs if immediate liquidity is the primary corporate goal.

Table 6. Quantitative Impact of Maximum Refund Exchange (90% Rate)

VII. Conclusion and Strategic Recommendations

The adoption of the 90% refund exchange rate for Qualified Small Biotechnology Companies under Public Act 25-168 solidifies Connecticut’s dedication to supporting its most innovative sector. This enhanced liquidity mechanism transforms unused tax credits into critical operating cash flow, providing early-stage biotech firms with a significant financial advantage. However, successful utilization requires rigorous adherence to statutory definitions and administrative procedures.

7.1. Summary of Key Compliance Checkpoints

The qualification process for the 90% refund is complex, requiring specific attention to three areas:

1. Definitional Rigor: Taxpayers must unequivocally meet the CGS § 12-217j definition of “biotechnology company,” requiring documented application of specific biological technologies (e.g., recombinant DNA, cell fusion) rather than merely operating in a health-related sector.11
2. Financial Threshold Compliance: Strict adherence to the $\$70$ million prior-year gross income threshold is mandatory for exchange eligibility, distinguishing the company from the larger cohort of QSBs eligible only for the 6% RDC calculation rate.4
3. Procedural Accuracy: The necessity of filing Form CT-1120 XCH separately from the primary corporate tax return (CT-1120), typically involving a simultaneous electronic filing and physical mailing, presents a critical administrative compliance risk that must be managed diligently.16

7.2. Strategic Recommendations for Tax Directors

Based on the statutory framework and quantitative analysis, the following strategic recommendations are crucial for Tax Directors managing Qualified Small Biotechnology Companies in Connecticut:

7.2.1. Cash Flow Prioritization and Calculation Method

Companies focused exclusively on maximizing immediate cash liquidity should favor the Non-Incremental RDC Credit (6% calculation).1 This method offers a percentage of total current-year QREs, providing a stable and predictable credit value essential for accurate cash flow forecasting, unlike the Incremental RC Credit, which is subject to prior-year expenditure variability.

7.2.2. Optimized Modeling of the Cap

Financial planning must incorporate the $\$1.5$ million annual cash cap as the hard limit for benefit realization. Projections of Qualified Research Expenditures should aim to generate a credit value of exactly $\$1,666,667$ (at the 90% rate) to capture the full cash benefit efficiently. Any QREs planned beyond the level required to generate this threshold value should be viewed as generating long-term carryforward assets, not immediate working capital.

7.2.3. Management of Unused Carryforward Credits

Even when the cap is hit, the residual credit remains highly valuable. Tax managers must maintain detailed tracking of any credits carried forward (up to 15 years).4 Accurate documentation and tracking of this carryforward balance are essential for mitigating future corporate business tax liability once the company achieves profitability.

7.2.4. Monitoring State Guidance

Given that the 90% exchange rate is a newly implemented provision effective for the 2025 income year, tax professionals should actively monitor the Connecticut Department of Revenue Services (DRS) for updated instructional booklets or official Policy Statements. These documents will provide definitive guidance on form completion specific to the 90% exchange, ensuring absolute compliance with any form revisions (particularly to Form CT-1120 XCH) issued after the effective date.5

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/